Tenaya Therapeutics Inc Ownership
$0.41
4.58%
Nasdaq, Oct 15, 04:36 pm EDT.
Closed.
Tenaya Therapeutics Inc Top Shareholders
| # | Holder | Shares | % of Shares Out | Change | Filing Date |
|---|---|---|---|---|---|
| 1 |
The Column Group LP
|
49.314m | 21.99% | -9.400m | Feb 25 2026 |
| 2 |
Millennium Management LLC
|
11.582m | 5.17% | +5.152m | Aug 17 2026 |
| 3 |
Vanguard Capital Management, LLC
|
7.101m | 3.17% | -1.381m | Jun 30 2026 |
| 4 |
Citadel Advisors LLC
|
4.567m | 2.04% | +366.774k | Jun 30 2026 |
| 5 |
Renaissance Technologies LLC
|
4.281m | 1.91% | +567.339k | Jun 30 2026 |
|
1
The Column Group LP
|
21.99%
49.314m
|
|
2
Millennium Management LLC
|
5.17%
11.582m
|
|
3
Vanguard Capital Management, LLC
|
3.17%
7.101m
|
|
4
Citadel Advisors LLC
|
2.04%
4.567m
|
|
5
Renaissance Technologies LLC
|
1.91%
4.281m
|
| The largest shareholders show who really holds influence: big institutional owners shape a stock's liquidity, and building or cutting positions can move the price. | |
| The 5 largest shareholders together hold 34.27% of Tenaya Therapeutics Inc, with The Column Group LP the biggest at 21.99%, followed by Millennium Management LLC (5.17%) and Vanguard Capital Management, LLC (3.17%). |
Recent Tenaya Therapeutics Inc Insider Transactions
Powered by
| Date | Insider & Role | Type | Price | Quantity | Volume |
|---|---|---|---|---|---|
| Oct 16 2026 |
John Mitchell
CEO
|
Purchases
|
$182.45 | + 15,000 | $2,736,750 |
| Oct 13 2026 |
Sarah Chen
CFO
|
Sales
|
$179.80 | - 8,500 | $1,528,300 |
| Oct 09 2026 |
Robert Williams
COO
|
Purchases
|
$175.20 | + 12,000 | $2,102,400 |
| Oct 04 2026 |
Emily Rodriguez
Director
|
Sales
|
$181.30 | - 5,200 | $942,760 |
| Sep 28 2026 |
Michael Thompson
SVP Operations
|
Purchases
|
$170.50 | + 20,000 | $3,410,000 |
| Sep 21 2026 |
Lisa Park
General Counsel
|
Sales
|
$177.90 | - 6,800 | $1,209,720 |
| No transactions found for this filter. | |||||
|
John Mitchell
PURCHASES
|
Oct 16 2026
$182.45
|
|
Sarah Chen
SALES
|
Oct 13 2026
$179.80
|
|
Robert Williams
PURCHASES
|
Oct 09 2026
$175.20
|
|
Emily Rodriguez
SALES
|
Oct 04 2026
$181.30
|
|
Michael Thompson
PURCHASES
|
Sep 28 2026
$170.50
|
|
Lisa Park
SALES
|
Sep 21 2026
$177.90
|
| No transactions found for this filter. | |
| Insider transactions show you what executives, directors and major shareholders do with their own stock: people who know the company from the inside. Buys are the most telling signal, because insiders invest their own money. Sells are harder to read, since they can also be driven by taxes, diversification or expiring option programs. |
Tenaya Therapeutics Inc Short interest
Powered by
| Short interest shows what share of a stock's freely tradable shares (float) is currently sold short, meaning held by investors betting on falling prices. A high or rising level can be read two ways: it reflects the skepticism of many market participants, but also carries upside potential. Because if the stock rises, short sellers have to buy back, which can push the price up even further. This effect is called a short squeeze. | |
| The short interest in Tenaya Therapeutics Inc has fallen over the past 12 months from around 25.2% to 13.2% of the float. Fewer and fewer market participants are betting on falling prices. That points to easing skepticism, as short sellers increasingly unwind their positions. |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
